Ferroptosis inducer-13
Ferroptosis inducer-13 is a 5′-prenylated chalcone derivative that effectively induces ferroptosis in human non-small cell lung cancer (NSCLC) cells by altering the activity of the Nrf2/xCT/GPX4 pathway. Ferroptosis inducer-13 exhibits potent anti-proliferative effects in vitro, and inhibits tumour growth in a NSCLC mouse model. Ferroptosis inducer-13 can be used for NSCLC research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3085517-19-4
- Formule: C21H23NO3
- Masse moléculaire:337.41
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
GPX4 |
In Vitro
Ferroptosis inducer-13 (compound 4a) (72 h) exhibits potent broad-spectrum antiproliferative activity against cancer cells, with IC50 values of 2.11 μM (PC9), 2.17 μM (MDA-MB-231), 3.81 μM (SMMC-7721), and 4.10 μM (SGC-7901)[1].
Ferroptosis inducer-13 (0-40 μM; 24-72 h) exhibits significant anti-proliferative effects on NSCLC cells (PC9 and H1975) in a time- and concentration-dependent manner[1].
Ferroptosis inducer-13 (20 μM; 24 h) induces ferroptosis in NSCLC cells (PC9 and H1975)[1].
Ferroptosis inducer-13 (0-40 μM; 24 h) leads to GSH depletion and increases Fe2+, ROS and LPO levels, and induces ferroptosis through modulation of the Nrf2/xCT/GPX4 signaling pathway in PC9 and H1975 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PC9, H1975
-
Concentration:0, 2.5, 5, 10, 20, 40 μM
-
Incubation Time:24, 48, 72 h
-
Result:Gradually decreased cell viability of PC9 and H1975 cells in a concentration manner.
Exhibited significant anti-proliferative effects on NSCLC cells (PC9 and H1975) in a time- and concentration-dependent manner.
-
Cell Line:PC9, H1975
-
Concentration:20 μM
-
Incubation Time:12 h
-
Result:Significantly enhanced cell viability by approximately 20% when combined with ferroptosis inhibitor.
-
Cell Line:PC9, H1975
-
Concentration:20 μM
-
Incubation Time:24 h
-
Result:Moderately reversed the GPX expression when combined with ferroptosis inhibitor.
-
Cell Line:PC9, H1975
-
Concentration:0, 5, 10, 20, 40 μM
-
Incubation Time:24 h
-
Result:Significantly decreased Nrf2 levels in both cytoplasmic and nuclear fractions while reducing xCT and GPX4 expression.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Balb/c nude mice (16-20 g) subcutaneously injected with PC9 cells[1]
-
Dosage:2, 5 mg/kg
-
Administration:i.p.; every 3 days for 18 days
-
Result:Exhibited tumor growth suppression with minimal impact on body weight.
Caused no significant organ toxicity in mice.
Significantly downregulated the protein expression of xCT and GPX4 in tumor tissues compared with the control group.
Chemical Information
-
CAS No. 3085517-19-4
-
Masse moléculaire 337.41
-
Formule C21H23NO3
-
SMILES
COC1=CC(OC)=C(C=C1C(/C=C/C2=NC=CC=C2)=O)C/C=C(C)\C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)